Skip to main content

Table 3 Associations of serum uric acid with adverse cardiovascular events and all-cause mortality

From: Uric acid is a risk factor for ischemic stroke and all-cause mortality in the general population: a gender specific analysis from The Tromsø Study

 

Hazard ratio (95% CI) per 1 SD increase in serum uric acid (87 μmol/L)

 

Men (n = 2696)

P-value

Women (n = 3004)

P-value

Men and women ( n = 5700)

P-value

All-cause mortality

      

Unadjusted

1.01 (0.94, 1.09)

0.6

1.24 (1.14, 1.35)

<0.001

1.10 (1.04, 1.17)

<0.001

Age-adjusted

1.11 (1.03, 1.19)

0.005

1.12 (1.03, 1.22)

0.008

1.11 (1,05, 1.18)

<0.001

Multivariable adjustment

      

Model 1

1.13 (1.04, 1.22)

0.003

1.22 (1.12, 1.33)

<0.001

1.19 (1.14, 1.25)

<0.001

Model 2

1.13 (1.05, 1.23)

0.003

1.20 (1.10, 1.31)

0.001

1.17 (1.01, 1.24)

<0.001

Model 3

1.13 (1.04, 1.22)

0.005

1.20 (1.09, 1.32)

<0.001

1.16 (1,09, 1.23)

<0.001

Model 4

1.12 (1.04, 1.22)

0.005

1.20 (1.09, 1.31)

<0.001

1.16 (1.09, 1.23)

<0.001

Model 5

1.11 (1.02, 1.20)

0.02

1.16 (1.05, 1.29)

0.004

1.13 (1.06, 1.21)

<0.001

Myocardial infarction

      

Unadjusted

1.15 (1.05, 1.26)

0.003

1.38 (1.20, 1.59)

<0.001

1.21 (1.12, 1.31)

<0.001

Age-adjusted

1.22 (1.11, 1.34)

<0.001

1.21 (1.06, 1.40)

0.006

1.23 (1.14, 1.33)

<0.001

Multivariable adjustment

      

Model 1

1.16 (1.05, 1.28)

0.004

1.16 (1.01, 1.35)

0.049

1.16 (1.08, 1.27)

<0.001

Model 2

1.07 (0.95, 1.19)

0.25

1.09 (0.93, 1.27)

0.26

1.09 (0.99, 1.18)

0.09

Model 3

1.05 (0.94, 1.17)

0.3

1.10 (0.94, 1.29)

0.22

1.09 (0.10, 1.18)

0.06

Model 4

1.05 (0.95, 1.17)

0.3

1.09 (0.93, 1.27)

0.3

1.08 (0.99, 1.18)

0.09

Model 5

1.05 (0.94, 1.17)

0.4

1.06 (0.90, 1.25)

0.5

1.06 (0.97, 1.16)

0.19

Ischemic stroke

   

Unadjusted

1.13 (1.01, 1.28)

0.049

1.37 (1.17, 1.61)

<0.001

1.21 (1.10, 1.33)

<0.001

Age-adjusted

1.23 (1.08, 1.40)

0.001

1.20 (1.03, 1.40)

0.02

1.22 (1.11, 1.35)

<0.001

Multivariable adjustment

      

Model 1

1.25 (1.10, 1.42)

0.001

1.13 (0.95, 1.33)

0.17

1.19 (1.07, 1.31)

0.001

Model 2

1.29 (1.13, 1.47)

<0.001

1.13 (0.95, 1.34)

0.17

1.22 (1.09, 1.35)

<0.001

Model 3

1.28 (1.11, 1.46)

<0.001

1.13 (0.95, 1.35)

0.18

1.21 (1.09, 1.35)

<0.001

Model 4

1.28 (1.12, 1.47)

<0.001

1.12 (0.94, 1.34)

0.20

1.22 (1.09, 1.35)

<0.001

Model 5

1.31 (1.14, 1.50)

<0.001

1.13 (0.94, 1.36)

0.21

1.24 (1.11, 1.38)

<0.001

  1. The Tromsø Study.
  2. Model 1: Age, body mass index (BMI), systolic blood pressure (SBP) and diastolic blood pressure (DBP).
  3. Model 2: Model 1 + HDL-cholesterol and total cholesterol.
  4. Model 3: Model 2 + use of diuretics and other antihypertensive medication.
  5. Model 4: Model 3 + current smoking and physical activity (physical activity ≥1 hr per week; yes = 1 / no = 0), current smoking (yes = 1 / no = 0).
  6. Model 5: Model 4 + renal factors added (GFR the CKD-EPI and log ACR: GFR: CKD-EPI formula [17]. Log ACR: log albumin/creatinine ratio, mean of 3 urine samples). In analyses of men and women together, adjustment for gender is included in all models.
  7. Number of events during follow up: 659 fatal- or non-fatal myocardial infarctions, 430 fatal- or non-fatal ischemic strokes, and 1433 deaths from all causes.
Back to article page

BMC Cardiovascular Disorders

ISSN: 1471-2261

Contact us